Grifols (GIFLF) Other financing activities (2011 - 2022)
Grifols' (GIFLF) quarterly Other financing activities came in at -$2.8 million in Q4 2022, down 153.62% quarter-over-quarter from $5.3 million in Q1 2020.
Analysis
Grifols (GIFLF) Other financing activities (2011 - 2022) Analysis & Trends
Grifols (GIFLF) has reported Other financing activities for 11 consecutive years, with -$2.8 million the latest figure, recorded in Q4 2022.
- For the quarter ending Q4 2022, Other financing activities changed N/A year-over-year to -$2.8 million; the trailing twelve-month figure through Dec 2022 stood at $25.3 million (changed N/A YoY), and the FY2025 full-year result was $41.8 million, down 24.77% from the prior year.
- Other financing activities declined to -$2.8 million in Q4 2022 per GIFLF's latest filing, from $5.3 million in the prior quarter.
- Across five years, Other financing activities topped out at $11.6 million in Q1 2019 and bottomed at -$2.8 million in Q4 2022.
- Historically, Other financing activities has averaged $3.3 million across 4 years, with a median of $1.2 million in 2018.
- The sharpest annual moves came in 2018 and 2019: Other financing activities tumbled 102.12% in 2018, then surged 1701.54% in 2019.
- Over 4 years, Other financing activities stood at -$700817.4 in 2018, then jumped by 1701.54% to $11.2 million in 2019, then slumped by 52.75% to $5.3 million in 2020, then sank by 153.62% to -$2.8 million in 2022.
- According to Business Quant data, Other financing activities over the past three periods registered -$2.8 million, $5.3 million, and $11.2 million for Q4 2022, Q1 2020, and Q4 2019 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | -2.84 Mn |
| Mar 31, 2020 | 5.30 Mn |
| Dec 31, 2019 | 11.22 Mn |
| Mar 31, 2019 | 11.62 Mn |
| Dec 31, 2018 | -700,817.41 |
| Jun 30, 2018 | -2.48 Mn |
| Mar 31, 2018 | 1.18 Mn |
| Dec 31, 2017 | 181.96 Mn |
| Jun 30, 2017 | 116.86 Mn |
| Mar 31, 2017 | -103.56 Mn |
| Dec 31, 2016 | 6.06 Mn |
| Sep 30, 2016 | -54.75 Mn |
| Dec 31, 2015 | 4.29 Mn |
| Sep 30, 2015 | -2.97 Mn |
| Jun 30, 2015 | 30.03 Mn |
| Mar 31, 2015 | -12.81 Mn |
| Dec 31, 2014 | 17.88 Mn |
| Sep 30, 2014 | 11.69 Mn |
| Jun 30, 2014 | -3.53 Mn |
| Mar 31, 2014 | 3.77 Mn |